Genentech seeks expanded FDA approval for Avastin

12/3/2007 | Bloomberg

Genentech has applied for regulatory approval to market Avastin as a treatment for breast cancer. The move follows a successful clinical trial of Avastin, in which 722 breast cancer patients who took the drug with the chemotherapy agent paclitaxel had stable tumors for an average of 11 months, compared to six months in the control group. FDA advisers are scheduled to meet Wednesday to consider the company's request.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA